At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 576 enrolled
Drug / intervention
losartan potassium +2 moredrug
Likely dose
losartan potassium 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Antihypertensive Efficacy and Safety of Different Doses of DuP 753 (MK0954)
In Brief
A Phase 3 clinical trial evaluating losartan potassium, Placebo, and 1 other intervention for Hypertension. Completed, enrolled 576 participants.
Detailed Summary
The purpose of this study was to compare the antihypertensive efficacy of different doses of losartan compared to placebo and enalapril, in patients with supine diastolic blood pressure of 100-115 mmHg.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 1990
Primary CompletionAug 1991
Study CompletionJan 1992
First PostedApr 2009
TodayJul 2026
First PostedApr 16, 2009
Enrollment StartDec 1, 1990
Primary CompletionAug 1, 1991
Study CompletionJan 1, 1992
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.2 years ago
Interventions
losartan potassiumdrug
losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
Placebodrug
Placebo capsule to losartan
Enalaprildrug
Enalapril 20 mg oral tablet taken once daily for 8 weeks